Belite Bio Inc. ADS/$BLTE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Belite Bio Inc. ADS
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
- Ticker
- $BLTE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 41
- Headquarters
- San Diego, United States
- Website
- www.belitebio.com
BLTE Metrics
BasicAdvanced
$6.2B
-
-$2.74
-1.22
-
Price and volume
Market cap
$6.2B
Beta
-1.22
52-week high
$200.00
52-week low
$102.00
Average daily volume
156K
Financial strength
Current ratio
33.561
Interest coverage (TTM)
-59,343.00%
Profitability
EBITDA (TTM)
-118.494
Effective tax rate (TTM)
-0.05%
Management effectiveness
Return on assets (TTM)
-15.65%
Return on equity (TTM)
-22.10%
Valuation
Price to book
7.99
Price to tangible book (TTM)
7.99
Growth
Earnings per share change (TTM)
75.83%
3-year earnings per share growth (CAGR)
44.36%
Bulls say / Bears say
Tinlarebant met its Phase 3 Stargardt trial’s primary endpoint, slowing retinal-lesion growth by 35.7% versus placebo, and the FDA has accepted its application for Priority Review with a decision target of 12 February 2027. If approved, it could become the first treatment for this disease. (Belite Bio)
Belite has filed for approval in Singapore, the UK and Switzerland, adding to accepted applications in the US and Japan. These parallel reviews could broaden tinlarebant’s reach beyond the US if it wins approval. (BioSpace)
The Phase 3 PHOENIX trial in geographic atrophy has enrolled 530 patients, with an interim analysis planned. Positive results could give tinlarebant a second significant retinal-disease opportunity beyond Stargardt. (Belite Bio)
The Phase 3 benefit was measured through retinal imaging, while visual acuity showed little difference between treatment and placebo. That leaves uncertainty over how clearly the lesion-growth result translates into a noticeable benefit for patients. (Ophthalmology Times)
Tinlarebant can cause delayed dark adaptation, night-vision difficulty and colour distortion. Two patients stopped treatment because of night-vision difficulty, which could make long-term use harder for some patients. (Ophthalmology Times)
Tinlarebant has not yet shown that it works in geographic atrophy: PHOENIX was still an ongoing Phase 3 trial in the company’s latest update. The Stargardt results therefore do not yet establish that the drug can deliver on this additional opportunity. (Belite Bio)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
BLTE Financial Performance
Revenues and expenses
BLTE Earnings Performance
Company profitability
Upcoming events
No upcoming events
BLTE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.